109 related articles for article (PubMed ID: 14595039)
1. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France.
Hamers FF; Rumeau-Pichon C
BMC Pediatr; 2012 Jun; 12():60. PubMed ID: 22681855
[TBL] [Abstract][Full Text] [Related]
3. Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) in the Irish Paediatric Population.
Mesbah Z; Sing Ho K; Fitzsimons P; Monavari AA; Mayne PD; Crushell E
Ir Med J; 2019 Dec; 112(10):1016. PubMed ID: 32311243
[TBL] [Abstract][Full Text] [Related]
4. 221 newborn-screened neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency: Findings from the Inborn Errors of Metabolism Collaborative.
Bentler K; Zhai S; Elsbecker SA; Arnold GL; Burton BK; Vockley J; Cameron CA; Hiner SJ; Edick MJ; Berry SA;
Mol Genet Metab; 2016 Sep; 119(1-2):75-82. PubMed ID: 27477829
[TBL] [Abstract][Full Text] [Related]
5. Personalised modelling of clinical heterogeneity between medium-chain acyl-CoA dehydrogenase patients.
Odendaal C; Jager EA; Martines AMF; Vieira-Lara MA; Huijkman NCA; Kiyuna LA; Gerding A; Wolters JC; Heiner-Fokkema R; van Eunen K; Derks TGJ; Bakker BM
BMC Biol; 2023 Sep; 21(1):184. PubMed ID: 37667308
[TBL] [Abstract][Full Text] [Related]
6. Visual screening for malignant melanoma: a cost-effectiveness analysis.
Losina E; Walensky RP; Geller A; Beddingfield FC; Wolf LL; Gilchrest BA; Freedberg KA
Arch Dermatol; 2007 Jan; 143(1):21-8. PubMed ID: 17224538
[TBL] [Abstract][Full Text] [Related]
7. Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis.
Pfeil J; Listl S; Hoffmann GF; Kölker S; Lindner M; Burgard P
Orphanet J Rare Dis; 2013 Oct; 8():167. PubMed ID: 24135440
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of clinical characteristics and ACADM gene variants in four children with Medium chain acyl-CoA dehydrogenase deficiency].
Xiao M; Xie Z; Liu J; Li X; Zhang Q; Zhang Z; Li D
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Jul; 40(7):787-794. PubMed ID: 37368378
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of routine screening for critical congenital heart disease in US newborns.
Peterson C; Grosse SD; Oster ME; Olney RS; Cassell CH
Pediatrics; 2013 Sep; 132(3):e595-603. PubMed ID: 23918890
[TBL] [Abstract][Full Text] [Related]
10. Management Principles for Acute Illness in Patients With Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency.
McGregor TL; Berry SA; Dipple KM; Hamid R;
Pediatrics; 2021 Jan; 147(1):. PubMed ID: 33372121
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of artificial intelligence-based diabetic retinopathy screening in rural China based on the Markov model.
Li H; Li G; Li N; Liu C; Yuan Z; Gao Q; Hao S; Fan S; Yang J
PLoS One; 2023; 18(11):e0291390. PubMed ID: 37971984
[TBL] [Abstract][Full Text] [Related]
12. A newborn Screening Programme for Inborn errors of metabolism in Galicia: 22 years of evaluation and follow-up.
Couce ML; Bóveda MD; Castiñeiras DE; Vázquez-Mosquera ME; Barbosa-Gouveia S; De Castro MJ; Iglesias-Rodríguez AJ; Colón C; Cocho JA; Sánchez P
Orphanet J Rare Dis; 2024 May; 19(1):202. PubMed ID: 38760795
[TBL] [Abstract][Full Text] [Related]
13. Incidence of medium-chain acyl-CoA dehydrogenase deficiency in Canada using the Canadian Paediatric Surveillance Program: Role of newborn screening.
Prasad C; Speechley KN; Dyack S; Rupar CA; Chakraborty P; Kronick JB
Paediatr Child Health; 2012 Apr; 17(4):185-9. PubMed ID: 23543005
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of medium chain acyl-CoA dehydrogenase deficiency (MCADD) and type 1 diabetes (T1D): a management challenge.
Afreh-Mensah D; Agwu JC
BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33762273
[TBL] [Abstract][Full Text] [Related]
15. Neonatal screening of inborn errors of metabolism using tandem mass spectrometry: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2003; 3(3):1-36. PubMed ID: 23074443
[TBL] [Abstract][Full Text] [Related]
16. Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme.
Bessey A; Chilcott JB; Leaviss J; Sutton A
Orphanet J Rare Dis; 2018 Oct; 13(1):179. PubMed ID: 30309370
[TBL] [Abstract][Full Text] [Related]
17. An economic evaluation of prolonged mechanical ventilation.
Cox CE; Carson SS; Govert JA; Chelluri L; Sanders GD
Crit Care Med; 2007 Aug; 35(8):1918-27. PubMed ID: 17581479
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia.
Castillo-Rodríguez L; Ovalle-Bracho C; Díaz-Jiménez D; Sánchez-Vanegas G; Muvdi-Arenas S; Castañeda-Orjuela C
PLoS One; 2019; 14(11):e0224351. PubMed ID: 31682606
[TBL] [Abstract][Full Text] [Related]
19. Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders.
Marsden D; Bedrosian CL; Vockley J
Genet Med; 2021 May; 23(5):816-829. PubMed ID: 33495527
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
